Related references
Note: Only part of the references are listed.Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis
Andrea J. Darzi et al.
BLOOD (2020)
Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis
Navkaranbir S. Bajaj et al.
PLOS MEDICINE (2019)
Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study
Gary E. Raskob et al.
BLOOD (2019)
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
Alex C. Spyropoulos et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
What the 2018 ASH venous thromboembolism guidelines omitted: nonadministration of pharmacologic prophylaxis in hospitalized patients
Oluwafemi P. Owodunni et al.
BLOOD ADVANCES (2019)
Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals
Anne-Celine Martin et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis
Benjamin Miao et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
Alexander T. Cohen
EUROPEAN HEART JOURNAL SUPPLEMENTS (2018)
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
Alex C. Spyropoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial
Arzu Kalayci et al.
THROMBOSIS AND HAEMOSTASIS (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
Holger J. Schunemann et al.
BLOOD ADVANCES (2018)
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
C. Michael Gibson et al.
CIRCULATION (2017)
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
G. Chi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy
C. Michael Gibson et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Design, rationale, and clinical implications
Gary E. Raskob et al.
THROMBOSIS AND HAEMOSTASIS (2016)
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial
A. T. Cohen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Hospital Performance for Pharmacologic Venous Thromboembolism Prophylaxis and Rate of Venous Thromboembolism A Cohort Study
Scott A. Flanders et al.
JAMA INTERNAL MEDICINE (2014)
Randomized Trial of Physician Alerts for Thromboprophylaxis after Discharge
Gregory Piazza et al.
AMERICAN JOURNAL OF MEDICINE (2013)
Relevance of Immobility and Importance of Risk Assessment Management for Medically Ill Patients
Russell D. Hull
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients REPLY
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population
Charles E. Mahan et al.
THROMBOSIS RESEARCH (2013)
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Alexander T. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Susan R. Kahn et al.
CHEST (2012)
Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients
Alpesh N. Amin et al.
JOURNAL OF HOSPITAL MEDICINE (2012)
Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE
Alex C. Spyropoulos et al.
CHEST (2011)
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Samuel Z. Goldhaber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Extended-Duration Venous Thromboembolism Prophylaxis in Acutely III Medical Patients With Recently Reduced Mobility
Russell D. Hull et al.
ANNALS OF INTERNAL MEDICINE (2010)
Computerized Decision Support for the Cardiovascular Clinician Applications for Venous Thromboembolism Prevention and Beyond
Gregory Piazza et al.
CIRCULATION (2009)
Venous thromboembolism (VTE) in Europe - The number of VTE events and associated morbidity and mortality
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2007)
Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism
Frederick A. Anderson et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial
AT Cohen et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Electronic alerts to prevent venous thromboembolism among hospitalized patients
N Kucher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients
PT Vaitkus et al.
THROMBOSIS AND HAEMOSTASIS (2005)
An association between atherosclerosis and venous thrombosis
P Prandoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
